For adeno-associated virus (AAV)-based gene therapies, the need for reliable and scalable production is paramount. Traditional production methods face issues with scalability and consistency, ...

Yet, their purification poses several production challenges and can require multiple costly steps. Workflows featuring multiple AAV purification steps can risk product loss and can waste valuable ...

In addition to AGTC, Solid Biosciences has adopted an HSV production system for its AAV production. Good help appears to be on the way. For more information, visit Vigene Biosciences.

However, scaling up AAV manufacturing to obtain sufficient yields to meet the demands of new research initiatives and clinical applications is challenging using traditional approaches. Download this ...

Yet, with this intensified interest in AAV therapies comes the need to scale-up viral production methods. As such, it’s imperative that successful viral production produce high titers that is ...

Download this compendium from The Scientist’s Creative Services Team and Polyplus, now part of Sartorius, to learn more about viral vectors for gene therapy and discover how to enhance recombinant AAV ...

They infected Sf9 cell lines — derived from the fall armyworm — with three different baculoviruses: two containing essential genes for AAV particle production (rep and cap), and one containing ...

Adeno-associated virus (AAV) are increasingly produced as they hold tremendous potential in gene therapy. At research level, small quantities are produced for proof of concept studies. However, scaled ...

This rapid, cost-effective, high-throughput solution addresses the critical need for precise product characterization in AAV vector production, enhancing process optimization and ensuring ...